Form 4: Tempest Therapeutics Officer Samuel Whiting Acquires Additional Shares

Samuel Whiting, Chief Medical Officer of Tempest Therapeutics, recently purchased 4,672 shares of common stock at a price of $2.13 per share.

Summary

• On July 2, 2024, Samuel Whiting, the Chief Medical Officer of Tempest Therapeutics, Inc., acquired 4,672 shares of common stock.
• The shares were purchased at a price of $2.13 per share.
• Following the transaction, Whiting directly owns 9,573 shares of Tempest Therapeutics common stock, which includes 3,000 shares acquired under the Issuer's stock purchase plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine insider transaction. The purchase could be seen as a positive signal, but without additional context, it's difficult to gauge the overall impact.

Positives

• An officer purchasing company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their trading activities. Monitoring these filings can offer insights into management's sentiment regarding the company's stock.

Stakeholder Impact

• The purchase of shares by a company officer could positively influence investor sentiment.

Key Dates